Time Lag Between Functional Change and Loss of Retinal Nerve Fiber Layer in Glaucoma.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
02 11 2020
Historique:
entrez: 3 11 2020
pubmed: 4 11 2020
medline: 8 5 2021
Statut: ppublish

Résumé

It is often suggested that structural change is detectable before functional change in glaucoma. However, this may be related to the lower variability and hence narrower normative limits of structural tests. In this study, we ask whether a time lag exists between the true rates of change in structure and function, regardless of clinical detectability of those changes. Structural equation models were used to determine whether the rate of change in function (mean linearized total deviation, AveTDLin) or structure (retinal nerve fiber layer thickness [RNFLT]) was predicted by the concurrent or previous rate for the other modality, after adjusting for its own rate in the previous time interval. Rates were calculated over 1135 pairs of consecutive visits from 318 eyes of 164 participants in the Portland Progression Project, with mean 207 days between visits. The rate of change of AveTDLin was predicted by its own rate in the previous time interval, but not by rates of RNFLT change in either the concurrent or previous time interval (both P > 0.05). Similarly, the rate of RNFLT change was not predicted by concurrent AveTDLin change after adjusting for its own previous rate. However, the rate of AveTDLin change in the previous time interval did significantly improve prediction of the current rate for RNFLT, with P = 0.005, suggesting a time lag of around six months between changes in AveTDLin and RNFLT. Although RNFL thinning may be detectable sooner, true functional change appears to predict and precede thinning of the RNFL in glaucoma.

Identifiants

pubmed: 33141891
pii: 2771921
doi: 10.1167/iovs.61.13.5
pmc: PMC7645201
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5

Subventions

Organisme : NEI NIH HHS
ID : R01 EY020922
Pays : United States

Références

Am J Ophthalmol. 2017 Feb;174:1-8
pubmed: 27818206
Ophthalmology. 2000 Sep;107(9):1688-92
pubmed: 10964831
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):26-35
pubmed: 30601928
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT404-12
pubmed: 27409499
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3667-3674
pubmed: 30029253
Ophthalmology. 2000 Oct;107(10):1809-15
pubmed: 11013178
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO180-BIO190
pubmed: 28715580
Prog Retin Eye Res. 2002 Jan;21(1):91-125
pubmed: 11906813
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2393-E2402
pubmed: 29463759
Invest Ophthalmol Vis Sci. 2013 Feb 15;54(2):1252-9
pubmed: 23349433
Curr Eye Res. 2016;41(3):273-83
pubmed: 26125320
Prog Retin Eye Res. 2010 Jul;29(4):249-71
pubmed: 20226873
J Glaucoma. 2019 Nov;28(11):945-951
pubmed: 31688445
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6540-8
pubmed: 20671278
Am J Ophthalmol. 1989 Aug 15;108(2):130-5
pubmed: 2757094
Transl Vis Sci Technol. 2013 Sep;2(6):3
pubmed: 24199032
Ophthalmology. 2013 Mar;120(3):535-543
pubmed: 23265804
Ophthalmology. 2006 Sep;113(9):1603-12
pubmed: 16949445
Am J Ophthalmol. 2016 Oct;170:75-82
pubmed: 27491698
Exp Eye Res. 2020 Jan;190:107873
pubmed: 31734278
Transl Vis Sci Technol. 2015 Apr 10;4(2):12
pubmed: 25909035
Ophthalmology. 2015 Sep;122(9):1786-94
pubmed: 26198806
Ophthalmology. 2015 Oct;122(10):2002-9
pubmed: 26198809
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4403-11
pubmed: 27564522
Invest Ophthalmol Vis Sci. 1989 Jun;30(6):1083-9
pubmed: 2732022
Arch Ophthalmol. 2005 Apr;123(4):464-70
pubmed: 15824218
Br J Ophthalmol. 2012 Jan;96(1):47-52
pubmed: 21478200
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):741-8
pubmed: 10711689
Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3662-8
pubmed: 17652736
Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3197-207
pubmed: 16123419
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3565-76
pubmed: 26047043
Br J Ophthalmol. 1978 May;62(5):327-9
pubmed: 656359
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):3984-3996
pubmed: 30098187
Graefes Arch Clin Exp Ophthalmol. 2012 Dec;250(12):1851-61
pubmed: 22527311
J Abnorm Psychol. 2003 Nov;112(4):545-57
pubmed: 14674868
Sociol Methods Res. 2008 Jan 1;36(4):462-494
pubmed: 19756246
Clin Exp Ophthalmol. 2012 May-Jun;40(4):369-80
pubmed: 22339936
Invest Ophthalmol Vis Sci. 2012 Nov 21;53(12):7766-73
pubmed: 23125332

Auteurs

Stuart K Gardiner (SK)

Devers Eye Institute, Legacy Research Institute, Portland, Oregon, United States.

Steven L Mansberger (SL)

Devers Eye Institute, Legacy Research Institute, Portland, Oregon, United States.

Brad Fortune (B)

Devers Eye Institute, Legacy Research Institute, Portland, Oregon, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH